Maggie L. Shaw

In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.

The bird flu, also known as avian influenza and H5N1, was implicated in the first human death from the infectious disease on January 6. But still, no human-to-human transmission has been reported.

In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.

With high biologic treatment failure rates common among patients who have hidradenitis suppurativa (HS), investigators set out to evaluate the potential of biomarkers to estimate potential treatment response.

Cochair of our recent Institute for Value-Based Medicine® event hosted with NYU Langone Health, Oscar B. Lahoud, MD, speaks on his hoped-for top health care priorities under the incoming administration.

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL from inception through October 4, 2024.

Alcohol was first identified as a carcinogen almost 40 years ago, by the World Health Organization's International Agency for Research on Cancer.

In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.

For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.

In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.

The Society for Pediatric Dermatology (SPD) Annual Meeting took place in Toronto, Canada, July 11-15, with our top coverage including the hot topics of combating misinformation and improving care for children with dermatologic conditions.

The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.

The 2024 World Conference on Lung Cancer (WCLC) took place in San Diego, California, from September 7 to 10, 2024.

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.

The 2024 American Academy of Dermatology conference was held in San Diego, California March 8 to 11.

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data showing both setbacks in clinical trial results and advancements in screening recommendations for at-risk patients.

Across 2024, top immunology news focused on ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis, highlighting studies on gut bacteria, radiographic progression, socioeconomic factors, and bimekizumab's persistent efficacy across multiple disease states.

In part 3 of our interview with hematologist-oncologist Don M. Benson, MD, PhD, The Ohio State University Comprehensive Cancer Center, he addresses the unpredictable nature of multiple myeloma outcomes and their multifactorial nature.

The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.

Since its founding in 2012, the National Association of ACOs has evolved from a group of 30 to 477 accountable care organization members covering 9.2 million beneficiary lives.

A new report from The Commonwealth Fund compares trends in health plan spending and employee costs for 2014 through 2023 between small and large businesses, taking into account plan premiums, employee contributions, and deductibles. It also highlights that although small firms do not even have to offer health benefits, large firms are required to do so by the Affordable Care Act.

To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome treatment resistance in non–small cell lung cancer.

In the continuation of our discussion with Chris Sayed, MD, University of North Carolina at Chapel Hill Department of Dermatology, he discusses the benefits of subcutaneous treatment of hidradenitis suppurativa, the chronic inflammatory skin condition.

These data from the Environmental Protection Agency were presented at the Society for Risk Analysis annual meeting.

This pair of posters presented at the 66th American Society of Hematology Annual Meeting & Exposition provides updates on epcoritamab, currently being investigated in the Epcore NHL-1 trial.

National Recovery Month is recognized each year in September, and for 2024, we marked the month with a special podcast and exclusive video series with our Strategic Alliance Partner, UPMC Health Plan.

Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.

Presentations at the 2024 Asembia Specialty Pharmacy Summit focused on reshaping specialty pharmacy while keeping patients front and center.

Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.

Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients who have unresectable stage III non–small cell lung cancer (NSCLC).